Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Beam Therapeutics

Vertex Pharmaceuticals

The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery.

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

Moderna

Moderna's pipeline programs may drive another huge phase of growth. The potential approval of CRISPR's first product could be a major catalyst for the stock.

Better Growth Stock: Moderna vs. CRISPR Therapeutics

Institutional investors might be on to something.

3 Things About CRISPR Therapeutics That Smart Investors Know

Beam Therapeutics could be a huge winner over the long run with its base-editing therapies.

3 Game-Changing Stocks to Buy in March

Fiverr

Investors are bidding up shares of these companies, and there are good reasons for doing so.

2 Soaring Stocks to Buy and Hold Through 2023 and Beyond

Axcelis Technologies

Amazon

ARK Genomic Revolution Multi-Sector ETF

Celsius Holdings

Alphabet

QUALCOMM

Target

United Rentals

Veeva Systems

These diversified growth stocks could add rocket fuel to your long-term investment portfolio.

10 Best Stocks to Buy in March 2023

CRISPR Therapeutics AG is a gene-editing startup that uses CRISPR/Cas9 technology to develop therapies. The company's most commercially promising therapy is the Exa-cel program, which is close to get to commercial stage.

Beyond Crispr's Exa-Cel Program: A Scalable Pipeline

ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.

CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Doximity

Doing this can strengthen your retirement plan.

Here's How Much You Can Make From Investing Your Tax Return Every Year

CRISPR Therapeutics AG (NASDAQ:CRSP ) Citi's 2023 Virtual Oncology Leadership Summit Conference February 22, 2023 1:00 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Yigal Nochomovitz - Citi Yigal Nochomovitz All right. Great. Welcome, everyone.

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2023 Virtual Oncology Leadership Summit Conference (Transcript)

Crispr's share price spiked a little this week on Q422 earnings. There's a much bigger story unfolding, however - a first-ever approval of a Crispr/Cas9 gene editing cell therapy.

Crispr Therapeutics: I Sense A Long Bull Run As First Approval Approaches

CRISPR Therapeutics AG (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock

Here is how CRISPR Therapeutics AG (CRSP) and Applied Molecular Transport Inc. (AMTI) have performed compared to their sector so far this year.

Has CRISPR Therapeutics (CRSP) Outpaced Other Medical Stocks This Year?

CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.

CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates

-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing Application (BLA) submission on track for completion by end of Q1 2023-

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Ginkgo Bioworks Holdings

Both are on the verge of fast growth, and they haven't had any major setbacks yet.

2 Bruised Growth Stocks to Buy While They're Cheap

NextEra Energy

These two companies are on track to flourish through the end of the decade.

2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer

If approved, CRISPR's first product may deliver blockbuster sales.

Beat the Dow Jones With CRISPR Therapeutics Stock

Editas Medicine

They're both at the cutting edge of gene-editing technology.

These 2 Biotech Stocks Could Soar in the Next Bull Market

CRISPR Therapeutics AG (NASDAQ:CRSP ) SVB Securities Global Biopharma Conference Call February 15, 2023 1:40 PM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Mani Foroohar - SVB Securities Mani Foroohar Good afternoon and good morning to those still on the West Coast. Welcome to this next session of our Annual Global Biopharma Conference here at SVB Securities.

CRISPR Therapeutics AG (CRSP) SVB Securities Global Biopharma Conference (Transcript)

BioMarin Pharmaceutical

Sight Sciences

These three companies are attractive targets for their potential.

3 Prime Healthcare Takeover Targets

The time is right for each of these great stocks.

The Best Stocks To Invest $5,000 in Right Now

Etsy

Novavax

All of these players are cheap today considering their growth potential.

These Cheap Growth Stocks Could Supercharge Your Portfolio

Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.

News for CRISPR Therapeutics Stock (CRSP)